Newborn screening, early treatment can cut sickle cell anaemia mortality: ICMR study
As many as 63,536 newborns were tested over a five year period from 2019- 2024 as part of the study on Newborn Screening for Sickle cell Disease conducted by the National Institute of Immunohaematology in Mumbai under the India Council of Medical Research (ICMR) across seven centres in high prevalence areas of India. The study is yet to be published.
The newborn screening program helps find out if a baby is born with Sickle Cell Disease (SCD), a serious inherited blood disorder, soon after birth, explained Manisha Madkaikar, director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur.
"If not detected early, this disease can cause life-threatening problems like severe infections, anaemia (low blood levels), and even strokes in infants," she stressed.
"Finding the disease early can save lives by allowing doctors to start treatment before problems begin," Prabhakar Kedar, Scientist F, ICMR-NIIH , who is the principal investigator of the study, said.
Babies diagnosed early can be given preventive antibiotics (like penicillin) to avoid infections and get regular checkups and care from specialists, Dr Madkaikar said.
Early detection also helps in getting important vaccines to protect against serious illnesses while parents can also be taught the signs of danger so they can act quickly. It also helps families and doctors plan long-term treatment, provides genetic counselling to the family, and increases awareness, reducing the number of future cases, Dr Madkaikar explained.
This screening is especially important in tribal and high-risk areas of India, where many cases go undiagnosed, leading to early childhood deaths, Dr Kedar highlighted. "With screening, many of these deaths can be prevented," he said.
During the study, 7,275 babies (11.4 per cent) were found to be carriers of the sickle cell gene. This means they don't have the disease but can pass it on to their children, Dr Kedar said, adding, 569 babies (0.9 per cent) were found to have SCD.
These babies were followed up for the confirmation of diagnosis, parents were counselled about SCD, preventive measures to be taken for or to avoid complications, and informed about prenatal diagnosis to avoid any further births of affected children in the family.
"The babies were given comprehensive care, including penicillin prophylaxis, folic acid supplementation, appropriate vaccinations and hydroxyurea therapy, as indicated. This resulted in reduction in mortality in these children to less than 5 per cent from the earlier reported mortality of 20-30 per cent," Dr Kedar said.
This study shows that newborn screening works and can save lives, especially in places with a high number of cases like tribal areas, Dr Kedar said. This study was coordinated by Harpreet Kaur, senior scientists at ICMR, Delhi. "By detecting Sickle Cell Disease early, babies can get timely care, live healthier lives, and families can be better prepared," Dr Kedar said.
The seven centres which participated in the study are National Institute For Implementation Research on Non-Communicable Diseases in Jodhpur, Society for Education, Welfare and Action-Rural (SEWA -Rural) in Gujarat, the Nilgiris Adivasi Welfare Association (NAWA), Tamil Nadu, ICMR- National Institute for Research in Reproductive Health in Mumbai, ICMR-National Institute of Research in Tribal Health (NIRTH) in Jabalpur, ICMR-Regional Medical Research Centre, Bhubaneswar and ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Chandrapur.
Of the total 63,536 newborns tested, 57 per cent belonged to tribal parents and rest from others, Dr Kedar informed. The aim of the study was also to understand the regional variability and role of genetic modifiers in sickle cell disease as well as to identify barriers for newborn screening implementation, he explained.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
11 hours ago
- Hindustan Times
A comprehensive effort to contain sickle cell disease
Many within India's tribal communities have been silently battling the debilitating genetic disorder known as Sickle Cell Disease (SCD). For decades, this condition has taken a toll on their health and socioeconomic development, exacerbated further by geographic isolation and limited access to health care. Recognising this dire need, the Union government launched the National Sickle Cell Anaemia Elimination Mission (NSCAEM) in July 2023. This groundbreaking initiative seeks to not only eliminate sickle cell genetic transmission but also restore dignity and health to millions affected by this condition. In its first two years, the National Sickle Cell Anaemia Elimination Mission has yielded remarkable results, with joint efforts of MoHFW and the states, with over 60.7 million individuals have been screened across more than 300 districts in 17 high-prevalence states. (HT Archive) Sickle cell disease alters the shape of red blood cells, impairing their oxygen-carrying capacity and leading to severe health complications over time. Among tribal populations, the impact is profound, as they are disproportionately affected by this genetic disorder. According to Global Burden of Disease figures (2021), an estimated 82,500 births with SCD occur in India. The National Health Policy 2017 laid the groundwork for addressing this crisis. Building on this, the 2023 budget announced the NSCAEM, setting a target to screen 70 million individuals under 40 years by FY26. The activity was implemented under the ministry of health and family welfare (MoHFW), making it one of the largest population-based genetic screening programmes globally. The mission also aims to eliminate genetic transmission of SCD by 2047 while providing comprehensive care to those already afflicted. In its first two years, this mission has yielded remarkable results, with joint efforts of MoHFW and the states. As on July 31, over 60.7 million individuals have been screened across more than 300 districts in 17 high-prevalence states. Among those screened, 216,000 individuals were found to suffer from the disease, while 1.69 million were identified as carriers. Analysis reveals that 95% of cases are concentrated in five states: Odisha, Madhya Pradesh, Gujarat, Chhattisgarh, and Maharashtra. The story of Meena, a young tribal girl from Nawapara Ambikapur, Chhattisgarh, is emblematic of the mission's impact. Diagnosed during the screening drive, Meena was enrolled in a nearby health sub-centre. The trained Community Health Officer (CHO), auxiliary nurse midwife (ANM) and ASHA worker at the sub-centre ensured that she had access to free hydroxyurea, the drug that significantly alleviated the symptoms of SCD. Today, Meena leads a healthier life and is an advocate for genetic counselling in her community. To accelerate screening efforts, point-of-care (PoC) diagnostic devices approved by the Indian Council of Medical Research (ICMR) have been deployed. Initially limited to three, the number of approved kits has now expanded to over 30, reducing costs dramatically from ₹100 to ₹28 per kit. This initiative has ensured cost-effective and efficient diagnostic capabilities. The implementation of this mission is not solely focused on screening; it prioritises holistic care for individuals diagnosed with SCD. Management interventions under the mission include free health care services with access to essential medicines and diagnostics, hydroxyurea, a key drug for managing SCD, is added to the National Essential Drug list (EDL). The mission also emphasises genetic counselling and public awareness as pivotal strategies for eliminating SCD. Over 26.2 million genetic status cards have been distributed, empowering individuals with critical health information. SCD cards have become a vital tool for informed decision-making, enabling families to make choices that reduce the risk of genetic transmission. Fifteen health care institutions/medical colleges have been selected to establish Centres of Excellence (CoEs), as per guidelines laid down by the MoHFW, and funding support from the ministry of tribal affairs. These institutions focus on prenatal diagnosis and management of severe SCD complications, ensuring specialised care for at-risk families. Additionally, a National Level Training of Trainers (ToT) programme organised in October 2024 has equipped health care professionals with the skills and knowledge needed to address the complexities of SCD management effectively. The success of NSCAEM is underpinned by the whole-of-government approach, by which MoHFW is involving the tribal affairs, social justice & empowerment, education, and women & child development ministries. This inter-ministerial coordination ensures holistic implementation, addressing the socio-cultural and geographic dimensions of tribal health. Research-backed interventions, supported by the department of health research of the MoHFW, have further enhanced cost-effectiveness and patient outcomes. While the achievements are commendable, MoHFW has now shifted focus to future priorities for the mission. The immediate focus will be on expanding genetic counselling, public awareness campaigns, and distribution of genetic status cards. Leveraging community-level platforms will be crucial in ensuring that every carrier and diseased individual receives the care and support they need. Enhanced research efforts will provide actionable insights to refine interventions further. The true spirit of this mission lies in its motto: 'Supporting our fighters, strengthening our survivors, and standing by our warriors.' By combining political will, scientific innovation, and grassroots implementation, India is poised to eliminate sickle cell anaemia and transform the lives of millions. As India strides confidently towards its 2047 goal of eliminating SCD, the NSCAEM stands as a beacon of hope. It exemplifies what can be achieved when government, healthcare professionals, and communities unite for a common cause. India's fight against sickle cell anaemia is not just about combating a genetic disorder — it is a commitment to equity, dignity, and the health of our nation's most marginalised groups. With the experience of individuals like Meena guiding the way, the mission serves as a testament to the transformative power of targeted health care initiatives, marking a historic leap in addressing tribal health challenges. Jagat Prakash Nadda is the Union minister for health and family welfare. The views expressed are personal.
India Today
16 hours ago
- India Today
Saving the ‘Golden Hour': How STEMI ACT is helping India fight heart attack deaths
Heart attacks are killing more Indians than ever, and most don't get treatment in time. Over the past few years, news headlines and viral videos have told the same tragic story again and again: a man collapses mid-workout in a gym, a young professional faints while dancing at a wedding, an office-goer slumps at his desk — and never gets up. Across India, sudden heart attacks are claiming lives in homes, gyms, offices, and even on the cricket disease is now the number one killer in the country. The numbers are staggering: nearly three to four million people in India suffer a type of severe heart attack called ST-elevation myocardial infarction (STEMI) every year. This is a condition where a major artery in the heart is completely blocked, cutting off blood flow and threatening the survival of the heart to the Global Burden of Disease Study, cardiovascular diseases accounted for 28.1% of all deaths in India in 2016, up from 15.2% in 1990. But despite the scale of the crisis, there are simply not enough cardiologists, hospitals, or emergency systems in place to save lives, especially outside big cities in happens in a heart attack is that an artery in the heart gets blocked. A clot forms suddenly, like clotting in a wound, and stops blood flow. To save the heart muscle, we must restore blood flow immediately, either with a drug (thrombolysis) or emergency angioplasty (primary PCI).Primary PCI is the best option, but it's not available everywhere and certainly not 24/7 in India. The most effective window to save a life is known as the 'golden hour' - ideally within the first hour of in India, patients often take hours, even days, to get the right treatment.A MODEL THAT WORKS AND SAVES LIVESTo tackle this crisis, the STEMI ACT project, led by the Indian Council of Medical Research (ICMR) in collaboration with AIIMS, is building hub-and-spoke networks in states across model is simple: train doctors and paramedics in smaller 'spoke' hospitals to quickly diagnose STEMI using ECG and give clot-busting drugs immediately, while staying in contact with cardiologists at larger 'hub' hospitals via their pilot, thrombolysis rates jumped from 30% to 75%, and drugs were given within 40 minutes of first contact in over 90% of cases — well within the golden hour.'If a pizza can be delivered in 30 minutes, we can deliver life-saving treatment in 30 minutes too,' says Dr. S Ramakrishnan, cardiologist at AIIMS Delhi and National Principal Investigator of the ICMR STEMI ACT project.'In a country like India, a pharmaco-invasive approach, thrombolysis first, followed by angioplasty, is often the best option. The critical message is that 'time is life' and 'time is muscle'. Opening the artery quickly saves more of the heart. Unfortunately, the average time patients take to reach a hospital in India is far beyond the golden hour,' he tells SYSTEM PROBLEM: IT'S NOT JUST THE PATIENTOne of the biggest reasons for delay is misdiagnosis and poor emergency response systems.'The delay is not only due to patients. People don't know it's a heart attack, they go to the same clinic for chest pain that they would for fever or a headache. These smaller hospitals are often not equipped for heart attacks,' Dr. Ramakrishnan pointed out that treating a heart attack is not just about having good doctors or cath labs: 'You need an entire chain that works: from first medical contact to treatment.' The time it takes to reach a hospital in India with respect to heart attacks. The result of these delays is deadly. 'The death rate from heart attacks is about 10%, compared to 3–3.5% in the West. Most angioplasties here happen more than 24 hours after the attack, when much of the heart muscle is already dead,' he PARAMEDICS TO BEAT THE CLOCKGlobally, paramedics are often trained to diagnose and start treatment for heart attacks in ambulances. In India, this wasn't allowed until recently due to rules that prevented nurses and paramedics from giving medicines without a doctor's Ramakrishnan's team found a workaround: 'We made the ambulance an extension of AIIMS — so when I, as a doctor, give the order remotely, it's as if it is happening in AIIMS itself. If anything goes wrong, I take responsibility.'This allowed paramedics to give life-saving thrombolysis on the spot, cutting through traffic delays and hospital SUCCESS STORIESSome states have already adopted this model with remarkable success. Tamil Nadu offers free primary PCI 24/7 for eligible patients, Kerala has highly efficient district-level systems, and Goa runs a strong STEMI STEMI ACT, Andhra Pradesh treated 4,500 patients in a year, Punjab is set to thrombolyse STEMI patients at primary health centres, and states like Himachal Pradesh, Rajasthan, and Uttar Pradesh are expanding the of May 2025, nearly 6,000 STEMI patients had been registered under the PUBLIC HEALTH VISION'STEMI ACT aligns with India's broader cardiovascular disease management goals and ICMR's public health strategy by focusing on timely and effective treatment of a critical form of heart attack, STEMI,' says Meenakshi Sharma, Program Officer (Cardiovascular Diseases and Neurology) at the project highlights reducing the burden of non-communicable diseases like CVD through evidence-based interventions and timely action."Specifically, STEMI ACT addresses the critical 'golden hour' for treatment, reducing mortality and long-term morbidity associated with heart attacks, thereby contributing to the national effort to lower CVD-related deaths,' she improving care pathways, the project also strengthens the overall healthcare system's ability to handle cardiovascular disease — a key part of ICMR's national INDIANS ARE AT HIGHER RISK, AND YOUNGERSouth Asians, including Indians, suffer heart attacks 5–10 years earlier than Western populations. The reasons are a deadly mix of high cholesterol, diabetes, hypertension, abdominal obesity, smoking, stress, poor diet, and a lack of exercise.A 2018 Lancet Global Health study found that cardiovascular disease caused over 2.1 million deaths in India in 2015, including 1.3 million deaths between ages 30–69. Alarmingly, heart disease mortality rates in rural India have now surpassed those in even with systems in place, one major challenge remains, getting frontline doctors in rural and semi-urban areas to confidently administer thrombolytic drugs free of cost. Time is life when it comes to getting heart attack treatment. 'Administering thrombolysis for STEMI within the recommended window, ideally within 30 minutes of first medical contact, is particularly challenging in rural and semi-urban settings,' Meenakshi Sharma there are several hurdles:Many MBBS doctors fear complications like bleeding or believe thrombolysis should only be done in higher workers worry about legal liability or backlash from the community if something goes this fear will be crucial to saving more MINUTE COUNTSIndia's heart attack crisis is not unsolvable, but it demands urgency, awareness, and STEMI ACT project shows that with training, technology, and teamwork, life-saving treatment can be delivered within 30 minutes, even in remote for that to happen everywhere, experts say states must ensure uninterrupted supply of clot-busting drugs, equip ambulances and hospitals with ECG machines and defibrillators, train paramedics and medical officers in rapid diagnosis and treatment and run public awareness campaigns so people recognise heart attack symptoms and seek help in a heart attack, time is not just money — time is life.- EndsMust Watch
Time of India
2 days ago
- Time of India
Out of 6 cr people screened in 17 states, Sickle Cell Disease found in 2.16 lakh: JP Nadda in LS
New Delhi: Union Health Minister J P Nadda informed the Lok Sabha on Friday that 6.04 crore people in the 17 identified tribal-dominated states, including Maharashtra, have been screened for Sickle Cell Disease (SCD) till July 28, out of which 2,16,118 have been confirmed as diseased. Replying to a question, the health minister said the National Sickle Cell Anaemia Elimination Mission (NSCAEM) was launched by Prime Minister Narendra Modi from Madhya Pradesh on July 1, 2023 to eliminate SCD. The objectives of the mission are provision of affordable, accessible and quality care to all SCD patients, reduction in the prevalence of the disease through awareness creation, targeted screening of seven crore people till 2025-26 in the age group of 0-40 years in the affected districts of tribal areas and counselling through collaborative efforts of central ministries and state governments, he said. Screenings are conducted under NSCAEM at all health facilities from district hospitals up to Ayushman Arogya Mandir (AAM) level, Nadda said, adding, "As on 28.07.2025, a total of 6,04,50,683 population in the 17 identified tribal dominated states including Maharashtra have been screened, out of which 2,16,118 have been confirmed as diseased." Patients living with SCD are provided with services and facilities to improve their quality of life through AAMs, which include follow-up of individuals with the disease at frequent intervals, counselling regarding lifestyle management, pre-marriage and pre-natal decisions, nutritional supplementation support through the distribution of folic acid tablets, and management of crisis symptoms, as well as referral to higher-level facilities. As of July 28, 2,62,67,997 genetic counselling ID cards have been distributed in the country, Nadda said. Hydroxyurea has been included in the National Health Mission (NHM) Essential Drugs List at Sub-Health Centres, Primary Health Centres (PHC), Urban PHC, Community Health Centres (CHC) and District Hospitals to address the issue of access to medicine, the minister said. Under NHM, financial support is provided for the procurement of Hydroxyurea, to reduce the out-of-pocket expenditure borne by sickle cell anaemia patients. The Ministry of Health and Family Welfare (MoHFW) has issued guidelines for cost norms for the establishment of centres of excellence (CoE) on SCD funded by the Ministry of Tribal Affairs (MoTA) in various states. To date, 15 CoEs have been approved in the country by MoTA, Nadda informed. Through MoTA, awareness and counselling material have been developed and disseminated to the states and Union Territories (UTs). Through monthly Ayushman Arogya Shivirs, awareness is raised for various health programmes including SCD. The ministry provides technical and financial support to the states and UTs for conducting screenings and procurement of drugs for sickle cell anaemia, based on the proposals received in the form of programme implementation plans (PIPs) under NHM.
